The prominent expression of CCR2 in specific clinicopathologic/molecular subgroups of lung adenocarcinomas harboring oncogenic mutations in EGFR and KRAS, as well as in CRCs with microsatellite instability–high status further support the potential for refined patient selection. The gene discussed is KRAS; the disease is lung adenocarcinoma.